Findings

What do systematic reviews say?

1 questions · 1 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 100%Moderate 0 · 0%High 0 · 0%

Number of participants with gadolinium‐enhancing T1 lesions on MRI · patients with relapsing‐remitting multiple sclerosis

Ocrelizumab may leads to lower number of participants with gadolinium‐enhancing T1 lesions on MRI compared with interferon beta‐1a (low certainty).

1 finding from 1 review

Ocrelizumab for multiple sclerosis 2022 · Cochrane Headline outcomes only
RR 0.27 [0.22, 0.35]
2 studies · 1656 participants
Low